More medicine causes increased costs in Denmark

26 December 2023

In the first three quarters of 2023, Denmark’s expenditure on the purchase of hospital medicine rose by 2.5 % to almost 6.6 billion Danish kroner ($974.5 million).

The increase is solely due to rising consumption, show calculations from the Pharma industry Association (Lægemiddelindustriforeningen; Lif) based on figures from the regions' purchasing organization Amgros.

It is increasing consumption of medicine and not increasing prices that means that the regional hospitals in the first three quarters of 2023 should have more money out of their pockets. Exactly 163 million kroner, the Lif stated.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK